CANbridge Pharmaceuticals Inc.
北海康成製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1228)

VOLUNTARY ANNOUNCEMENT

ANNOUNCEMENT OF THE GRANT OF PRIORITY REVIEW STATUS OF CAN103 FOR THE TREATMENT OF GAUCHER DISEASE (GD)

This announcement is made by CANbridge Pharmaceuticals Inc. (the "**Company**", together with its subsidiaries and consolidated affiliated entities, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the "**Board**") hereby informs the shareholders and potential investors of the Company that CAN103 (velaglucerase-beta) for the treatment of Gaucher Disease (GD) has been granted priority review status by the Center for Drug Evaluation of the National Medical Products Administration of China.

The grant of priority review status of CAN103 (velaglucerase-beta) recognizes the high unmet need of Chinese GD patients and the strength of the Company's clinical trial results. The Company is working hard toward accelerating the approval of CAN103 (velaglucerase-beta) as the first domestically developed and manufactured enzyme replacement therapy in China.

INFORMATION ABOUT GAUCHER DISEASE (GD)

Gaucher Disease (GD), one of the most common lysosomal storage disorders, is a rare inherited genetic metabolic disease caused by autosomal recessive mutations in the GBA gene located on chromosome 1q22 and affects both males and females equally. GD is a clinical spectrum that comprises perinatal-lethal, Type I (chronic non-neuronopathic), Type II (acute neuronopathic), and Type III (chronic neuronopathic) forms, with Types I and III surviving into adulthood.

GD is caused by a deficiency of glucocerebrosidase (acid β-glucosidase), an enzyme that helps break down a cellular membrane glycosphingolipid called glucocerebroside (glucosylceramide) inside lysosomes. As a result, glucocerebroside accumulates primarily in cells of the monocyte-macrophage lineage (Gaucher cells) within certain organs, leading to splenomegaly, hepatomegaly, anemia, thrombocytopenia, bone pain and fractures, and in the most severe forms (perinatal-lethal, Types II and III), early neurological symptoms.

INFORMATION ABOUT CAN103 (VELAGLUCERASE-BETA)

CAN103 (velaglucerase-beta) is a recombinant human glucocerebrosidase enzyme replacement therapy that is being developed to treat GD Types I and III, which are the chronic non-neuronopathic and neuronopathic forms of the disease, respectively, that constitute the vast majority of patients. CAN103 (velaglucerase-beta) is administered as an intravenous infusion and is intended to supplement the lack of glucocerebrosidase in the lysosomes of GD patients.

INFORMATION ABOUT THE COMPANY

The Company is a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies for rare disease. It has a differentiated drug portfolio, with 3 approved drugs and a pipeline of 9 assets, targeting prevalent rare disease indications that have unmet needs and significant market potential. These include Hunter syndrome and other lysosomal storage disorders, paroxysmal nocturnal hemoglobinuria and other complement-mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases and neuromuscular diseases.

By Order of the Board
CANbridge Pharmaceuticals Inc.
北海康成製藥有限公司
Dr. James Qun Xue
Chairman

Hong Kong, September 30, 2024

As of the date of this announcement, the Board comprises Dr. James Qun Xue as executive Director, Dr. Fangxin Li as non-executive Director, and Dr. Richard James Gregory, Mr. James Arthur Geraghty, Mr. Peng Kuan Chan and Dr. Lan Hu as independent non-executive Directors.